nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—KDR—kidney cancer	0.123	0.463	CbGaD
Ponatinib—KIT—kidney cancer	0.116	0.437	CbGaD
Ponatinib—FGFR3—Pazopanib—kidney cancer	0.0607	0.124	CbGbCtD
Ponatinib—FGFR1—Pazopanib—kidney cancer	0.0291	0.0598	CbGbCtD
Ponatinib—FGFR2—Pazopanib—kidney cancer	0.0291	0.0598	CbGbCtD
Ponatinib—ABCB1—kidney cancer	0.0268	0.101	CbGaD
Ponatinib—KDR—Pazopanib—kidney cancer	0.0252	0.0517	CbGbCtD
Ponatinib—LYN—Pazopanib—kidney cancer	0.0223	0.0457	CbGbCtD
Ponatinib—KIT—Pazopanib—kidney cancer	0.02	0.041	CbGbCtD
Ponatinib—PDGFRA—Pazopanib—kidney cancer	0.02	0.041	CbGbCtD
Ponatinib—LCK—Pazopanib—kidney cancer	0.0182	0.0373	CbGbCtD
Ponatinib—FLT3—Erlotinib—kidney cancer	0.018	0.0369	CbGbCtD
Ponatinib—FGFR1—Sorafenib—kidney cancer	0.0169	0.0347	CbGbCtD
Ponatinib—KDR—Sorafenib—kidney cancer	0.0146	0.03	CbGbCtD
Ponatinib—RET—Sorafenib—kidney cancer	0.0146	0.03	CbGbCtD
Ponatinib—FLT3—Sorafenib—kidney cancer	0.0146	0.03	CbGbCtD
Ponatinib—FGFR2—Sunitinib—kidney cancer	0.0137	0.0281	CbGbCtD
Ponatinib—FGFR1—Sunitinib—kidney cancer	0.0137	0.0281	CbGbCtD
Ponatinib—RET—Sunitinib—kidney cancer	0.0118	0.0243	CbGbCtD
Ponatinib—FLT3—Sunitinib—kidney cancer	0.0118	0.0243	CbGbCtD
Ponatinib—KDR—Sunitinib—kidney cancer	0.0118	0.0243	CbGbCtD
Ponatinib—KIT—Sorafenib—kidney cancer	0.0116	0.0238	CbGbCtD
Ponatinib—PDGFRA—Sorafenib—kidney cancer	0.0116	0.0238	CbGbCtD
Ponatinib—ABL1—Erlotinib—kidney cancer	0.0103	0.0212	CbGbCtD
Ponatinib—PDGFRA—Sunitinib—kidney cancer	0.00941	0.0193	CbGbCtD
Ponatinib—KIT—Sunitinib—kidney cancer	0.00941	0.0193	CbGbCtD
Ponatinib—ABCB11—Paclitaxel—kidney cancer	0.00454	0.00931	CbGbCtD
Ponatinib—ABCB11—Vinblastine—kidney cancer	0.00398	0.00817	CbGbCtD
Ponatinib—ABCB11—Vincristine—kidney cancer	0.00392	0.00803	CbGbCtD
Ponatinib—CYP3A5—Temsirolimus—kidney cancer	0.00349	0.00715	CbGbCtD
Ponatinib—ABCG2—Pazopanib—kidney cancer	0.0033	0.00678	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—kidney cancer	0.00302	0.0062	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—kidney cancer	0.00245	0.00502	CbGbCtD
Ponatinib—ABCG2—Erlotinib—kidney cancer	0.00236	0.00484	CbGbCtD
Ponatinib—ABCB1—Temsirolimus—kidney cancer	0.00227	0.00465	CbGbCtD
Ponatinib—ABCG2—Paclitaxel—kidney cancer	0.00216	0.00443	CbGbCtD
Ponatinib—CYP2D6—Temsirolimus—kidney cancer	0.00214	0.00438	CbGbCtD
Ponatinib—CYP3A4—Everolimus—kidney cancer	0.00201	0.00413	CbGbCtD
Ponatinib—ABCG2—Sorafenib—kidney cancer	0.00192	0.00393	CbGbCtD
Ponatinib—ABCG2—Vincristine—kidney cancer	0.00186	0.00382	CbGbCtD
Ponatinib—CYP2C8—Pazopanib—kidney cancer	0.00176	0.00361	CbGbCtD
Ponatinib—ABCG2—Sunitinib—kidney cancer	0.00155	0.00319	CbGbCtD
Ponatinib—FGFR4—nephron tubule—kidney cancer	0.00137	0.0452	CbGeAlD
Ponatinib—CYP3A4—Temsirolimus—kidney cancer	0.00136	0.00279	CbGbCtD
Ponatinib—CYP3A5—Erlotinib—kidney cancer	0.00131	0.00268	CbGbCtD
Ponatinib—CYP2C8—Erlotinib—kidney cancer	0.00126	0.00258	CbGbCtD
Ponatinib—FGFR4—renal system—kidney cancer	0.00125	0.0411	CbGeAlD
Ponatinib—FGFR4—kidney—kidney cancer	0.00121	0.0397	CbGeAlD
Ponatinib—CYP3A5—Paclitaxel—kidney cancer	0.0012	0.00245	CbGbCtD
Ponatinib—ABCB1—Pazopanib—kidney cancer	0.00119	0.00244	CbGbCtD
Ponatinib—FGFR4—cortex of kidney—kidney cancer	0.00117	0.0387	CbGeAlD
Ponatinib—ABCG2—Doxorubicin—kidney cancer	0.00116	0.00239	CbGbCtD
Ponatinib—CYP2C8—Paclitaxel—kidney cancer	0.00115	0.00236	CbGbCtD
Ponatinib—CYP2D6—Pazopanib—kidney cancer	0.00112	0.0023	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—kidney cancer	0.00109	0.00223	CbGbCtD
Ponatinib—CYP3A5—Sorafenib—kidney cancer	0.00106	0.00218	CbGbCtD
Ponatinib—CYP3A5—Vincristine—kidney cancer	0.00103	0.00211	CbGbCtD
Ponatinib—CYP2C8—Sorafenib—kidney cancer	0.00102	0.00209	CbGbCtD
Ponatinib—FGFR4—Vinblastine—Vincristine—kidney cancer	0.000948	0.666	CbGdCrCtD
Ponatinib—ABCB1—Gemcitabine—kidney cancer	0.000861	0.00177	CbGbCtD
Ponatinib—CYP3A5—Sunitinib—kidney cancer	0.000861	0.00176	CbGbCtD
Ponatinib—FGFR3—renal system—kidney cancer	0.000851	0.028	CbGeAlD
Ponatinib—ABCB1—Erlotinib—kidney cancer	0.00085	0.00174	CbGbCtD
Ponatinib—FGFR3—kidney—kidney cancer	0.000823	0.0271	CbGeAlD
Ponatinib—BCR—nephron tubule—kidney cancer	0.00081	0.0267	CbGeAlD
Ponatinib—FGFR3—cortex of kidney—kidney cancer	0.000801	0.0264	CbGeAlD
Ponatinib—CYP2D6—Erlotinib—kidney cancer	0.000801	0.00164	CbGbCtD
Ponatinib—ABCB1—Paclitaxel—kidney cancer	0.000778	0.0016	CbGbCtD
Ponatinib—FGFR3—gonad—kidney cancer	0.000763	0.0251	CbGeAlD
Ponatinib—BCR—renal system—kidney cancer	0.000737	0.0242	CbGeAlD
Ponatinib—CYP3A4—Pazopanib—kidney cancer	0.000714	0.00146	CbGbCtD
Ponatinib—BCR—cortex of kidney—kidney cancer	0.000693	0.0228	CbGeAlD
Ponatinib—ABCB1—Sorafenib—kidney cancer	0.000691	0.00142	CbGbCtD
Ponatinib—ABCB1—Vinblastine—kidney cancer	0.000683	0.0014	CbGbCtD
Ponatinib—ABCB1—Vincristine—kidney cancer	0.000671	0.00138	CbGbCtD
Ponatinib—BCR—gonad—kidney cancer	0.00066	0.0217	CbGeAlD
Ponatinib—BCR—cardiac atrium—kidney cancer	0.00066	0.0217	CbGeAlD
Ponatinib—FLT3—gonad—kidney cancer	0.000656	0.0216	CbGeAlD
Ponatinib—CYP2D6—Sorafenib—kidney cancer	0.000651	0.00134	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—kidney cancer	0.000643	0.00132	CbGbCtD
Ponatinib—FGFR1—cortex of kidney—kidney cancer	0.000617	0.0203	CbGeAlD
Ponatinib—CYP3A4—urine—kidney cancer	0.000605	0.0199	CbGeAlD
Ponatinib—CYP2D6—urine—kidney cancer	0.000595	0.0196	CbGeAlD
Ponatinib—FGFR1—cardiac atrium—kidney cancer	0.000587	0.0193	CbGeAlD
Ponatinib—RET—renal system—kidney cancer	0.000586	0.0193	CbGeAlD
Ponatinib—RET—kidney—kidney cancer	0.000567	0.0187	CbGeAlD
Ponatinib—ABCB1—Sunitinib—kidney cancer	0.00056	0.00115	CbGbCtD
Ponatinib—FGFR2—renal system—kidney cancer	0.000557	0.0183	CbGeAlD
Ponatinib—FGFR2—kidney—kidney cancer	0.000539	0.0177	CbGeAlD
Ponatinib—TEK—renal system—kidney cancer	0.000534	0.0176	CbGeAlD
Ponatinib—TEK—kidney—kidney cancer	0.000516	0.017	CbGeAlD
Ponatinib—CYP3A4—Erlotinib—kidney cancer	0.000509	0.00104	CbGbCtD
Ponatinib—TEK—cortex of kidney—kidney cancer	0.000503	0.0166	CbGeAlD
Ponatinib—PDGFRA—renal system—kidney cancer	0.000484	0.0159	CbGeAlD
Ponatinib—KDR—nephron tubule—kidney cancer	0.00048	0.0158	CbGeAlD
Ponatinib—TEK—cardiac atrium—kidney cancer	0.000478	0.0157	CbGeAlD
Ponatinib—SRC—renal system—kidney cancer	0.000475	0.0156	CbGeAlD
Ponatinib—Nilotinib—BRAF—kidney cancer	0.000468	0.172	CrCbGaD
Ponatinib—CYP3A4—Paclitaxel—kidney cancer	0.000466	0.000956	CbGbCtD
Ponatinib—SRC—kidney—kidney cancer	0.000459	0.0151	CbGeAlD
Ponatinib—KDR—renal system—kidney cancer	0.000437	0.0144	CbGeAlD
Ponatinib—PDGFRA—gonad—kidney cancer	0.000434	0.0143	CbGeAlD
Ponatinib—KIT—nephron tubule—kidney cancer	0.000426	0.014	CbGeAlD
Ponatinib—SRC—gonad—kidney cancer	0.000426	0.014	CbGeAlD
Ponatinib—SRC—cardiac atrium—kidney cancer	0.000425	0.014	CbGeAlD
Ponatinib—KDR—kidney—kidney cancer	0.000422	0.0139	CbGeAlD
Ponatinib—ABCB1—Doxorubicin—kidney cancer	0.000419	0.00086	CbGbCtD
Ponatinib—CYP3A4—Sorafenib—kidney cancer	0.000414	0.000849	CbGbCtD
Ponatinib—KDR—cortex of kidney—kidney cancer	0.000411	0.0135	CbGeAlD
Ponatinib—CYP3A4—Vinblastine—kidney cancer	0.000409	0.000839	CbGbCtD
Ponatinib—CYP3A4—Vincristine—kidney cancer	0.000402	0.000825	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—kidney cancer	0.000395	0.00081	CbGbCtD
Ponatinib—KDR—cardiac atrium—kidney cancer	0.000391	0.0129	CbGeAlD
Ponatinib—KIT—renal system—kidney cancer	0.000387	0.0127	CbGeAlD
Ponatinib—Nilotinib—KIT—kidney cancer	0.000375	0.138	CrCbGaD
Ponatinib—KIT—kidney—kidney cancer	0.000374	0.0123	CbGeAlD
Ponatinib—ABL1—nephron tubule—kidney cancer	0.000371	0.0122	CbGeAlD
Ponatinib—KIT—cortex of kidney—kidney cancer	0.000364	0.012	CbGeAlD
Ponatinib—Nilotinib—CA9—kidney cancer	0.000361	0.133	CrCbGaD
Ponatinib—KIT—gonad—kidney cancer	0.000347	0.0114	CbGeAlD
Ponatinib—ABL1—renal system—kidney cancer	0.000337	0.0111	CbGeAlD
Ponatinib—CYP3A4—Sunitinib—kidney cancer	0.000336	0.000688	CbGbCtD
Ponatinib—ABL1—kidney—kidney cancer	0.000326	0.0107	CbGeAlD
Ponatinib—Nilotinib—CA2—kidney cancer	0.000324	0.119	CrCbGaD
Ponatinib—ABL1—cortex of kidney—kidney cancer	0.000317	0.0104	CbGeAlD
Ponatinib—Imatinib—KIT—kidney cancer	0.000313	0.115	CrCbGaD
Ponatinib—ABL1—gonad—kidney cancer	0.000302	0.00994	CbGeAlD
Ponatinib—ABL1—cardiac atrium—kidney cancer	0.000302	0.00993	CbGeAlD
Ponatinib—Imatinib—CA9—kidney cancer	0.000301	0.111	CrCbGaD
Ponatinib—Imatinib—CA2—kidney cancer	0.00027	0.0994	CrCbGaD
Ponatinib—CYP3A4—Doxorubicin—kidney cancer	0.000251	0.000515	CbGbCtD
Ponatinib—ABCG2—nephron tubule—kidney cancer	0.000234	0.00769	CbGeAlD
Ponatinib—CYP2C8—renal system—kidney cancer	0.000218	0.00719	CbGeAlD
Ponatinib—CYP3A5—nephron tubule—kidney cancer	0.000217	0.00714	CbGeAlD
Ponatinib—CYP2C8—kidney—kidney cancer	0.000211	0.00695	CbGeAlD
Ponatinib—CYP3A5—renal system—kidney cancer	0.000197	0.00649	CbGeAlD
Ponatinib—CYP3A5—kidney—kidney cancer	0.000191	0.00627	CbGeAlD
Ponatinib—CYP3A5—cortex of kidney—kidney cancer	0.000186	0.00611	CbGeAlD
Ponatinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	0.000159	0.111	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	0.000159	0.111	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	0.000159	0.111	CbGdCrCtD
Ponatinib—Imatinib—PTGS1—kidney cancer	0.000148	0.0546	CrCbGaD
Ponatinib—CYP3A4—renal system—kidney cancer	0.000148	0.00487	CbGeAlD
Ponatinib—CYP2D6—renal system—kidney cancer	0.000146	0.00479	CbGeAlD
Ponatinib—CYP3A4—kidney—kidney cancer	0.000143	0.00471	CbGeAlD
Ponatinib—CYP2D6—kidney—kidney cancer	0.000141	0.00463	CbGeAlD
Ponatinib—ABCB1—nephron tubule—kidney cancer	0.000115	0.00379	CbGeAlD
Ponatinib—ABCB1—renal system—kidney cancer	0.000105	0.00345	CbGeAlD
Ponatinib—ABCB1—kidney—kidney cancer	0.000101	0.00333	CbGeAlD
Ponatinib—ABCB1—cortex of kidney—kidney cancer	9.86e-05	0.00325	CbGeAlD
Ponatinib—ABCB1—gonad—kidney cancer	9.39e-05	0.00309	CbGeAlD
Ponatinib—Nilotinib—ABCB1—kidney cancer	8.65e-05	0.0318	CrCbGaD
Ponatinib—Imatinib—ABCB1—kidney cancer	7.21e-05	0.0265	CrCbGaD
Ponatinib—Dizziness—Erlotinib—kidney cancer	2.59e-05	0.00021	CcSEcCtD
Ponatinib—Connective tissue disorder—Capecitabine—kidney cancer	2.59e-05	0.000209	CcSEcCtD
Ponatinib—Vomiting—Everolimus—kidney cancer	2.58e-05	0.000209	CcSEcCtD
Ponatinib—Anaemia—Paclitaxel—kidney cancer	2.58e-05	0.000209	CcSEcCtD
Ponatinib—Paraesthesia—Vincristine—kidney cancer	2.58e-05	0.000209	CcSEcCtD
Ponatinib—Rash—Everolimus—kidney cancer	2.56e-05	0.000207	CcSEcCtD
Ponatinib—Dermatitis—Everolimus—kidney cancer	2.56e-05	0.000207	CcSEcCtD
Ponatinib—Headache—Vinblastine—kidney cancer	2.56e-05	0.000207	CcSEcCtD
Ponatinib—Headache—Everolimus—kidney cancer	2.55e-05	0.000206	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—kidney cancer	2.54e-05	0.000206	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—kidney cancer	2.54e-05	0.000206	CcSEcCtD
Ponatinib—Visual impairment—Capecitabine—kidney cancer	2.54e-05	0.000205	CcSEcCtD
Ponatinib—Asthenia—Sorafenib—kidney cancer	2.53e-05	0.000205	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—kidney cancer	2.52e-05	0.000203	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—kidney cancer	2.51e-05	0.000203	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—kidney cancer	2.51e-05	0.000203	CcSEcCtD
Ponatinib—Leukopenia—Paclitaxel—kidney cancer	2.5e-05	0.000202	CcSEcCtD
Ponatinib—Decreased appetite—Vincristine—kidney cancer	2.5e-05	0.000202	CcSEcCtD
Ponatinib—Pruritus—Sorafenib—kidney cancer	2.5e-05	0.000202	CcSEcCtD
Ponatinib—Vomiting—Erlotinib—kidney cancer	2.49e-05	0.000202	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	2.48e-05	0.000201	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Vincristine—kidney cancer	2.48e-05	0.000201	CcSEcCtD
Ponatinib—Fatigue—Vincristine—kidney cancer	2.48e-05	0.0002	CcSEcCtD
Ponatinib—Rash—Erlotinib—kidney cancer	2.47e-05	0.0002	CcSEcCtD
Ponatinib—Dermatitis—Erlotinib—kidney cancer	2.47e-05	0.0002	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Insomnia—Gemcitabine—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Eye disorder—Capecitabine—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Headache—Erlotinib—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Pain—Vincristine—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Constipation—Vincristine—kidney cancer	2.46e-05	0.000199	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	2.45e-05	0.000199	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—kidney cancer	2.45e-05	0.000199	CcSEcCtD
Ponatinib—Paraesthesia—Gemcitabine—kidney cancer	2.45e-05	0.000198	CcSEcCtD
Ponatinib—Flushing—Capecitabine—kidney cancer	2.45e-05	0.000198	CcSEcCtD
Ponatinib—Cardiac disorder—Capecitabine—kidney cancer	2.45e-05	0.000198	CcSEcCtD
Ponatinib—Cough—Paclitaxel—kidney cancer	2.44e-05	0.000197	CcSEcCtD
Ponatinib—Asthenia—Sunitinib—kidney cancer	2.44e-05	0.000197	CcSEcCtD
Ponatinib—Dyspnoea—Gemcitabine—kidney cancer	2.43e-05	0.000196	CcSEcCtD
Ponatinib—Nausea—Vinblastine—kidney cancer	2.42e-05	0.000196	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—kidney cancer	2.42e-05	0.000195	CcSEcCtD
Ponatinib—Nausea—Everolimus—kidney cancer	2.41e-05	0.000195	CcSEcCtD
Ponatinib—Diarrhoea—Sorafenib—kidney cancer	2.41e-05	0.000195	CcSEcCtD
Ponatinib—Hypertension—Paclitaxel—kidney cancer	2.41e-05	0.000195	CcSEcCtD
Ponatinib—Pruritus—Sunitinib—kidney cancer	2.4e-05	0.000194	CcSEcCtD
Ponatinib—Angiopathy—Capecitabine—kidney cancer	2.39e-05	0.000193	CcSEcCtD
Ponatinib—Arthralgia—Paclitaxel—kidney cancer	2.38e-05	0.000192	CcSEcCtD
Ponatinib—Myalgia—Paclitaxel—kidney cancer	2.38e-05	0.000192	CcSEcCtD
Ponatinib—Mediastinal disorder—Capecitabine—kidney cancer	2.37e-05	0.000192	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—kidney cancer	2.37e-05	0.000192	CcSEcCtD
Ponatinib—Decreased appetite—Gemcitabine—kidney cancer	2.37e-05	0.000192	CcSEcCtD
Ponatinib—Chills—Capecitabine—kidney cancer	2.36e-05	0.000191	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	2.36e-05	0.000191	CcSEcCtD
Ponatinib—Arrhythmia—Capecitabine—kidney cancer	2.35e-05	0.00019	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	2.35e-05	0.00019	CcSEcCtD
Ponatinib—Fatigue—Gemcitabine—kidney cancer	2.35e-05	0.00019	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vincristine—kidney cancer	2.35e-05	0.00019	CcSEcCtD
Ponatinib—Dizziness—Sorafenib—kidney cancer	2.33e-05	0.000189	CcSEcCtD
Ponatinib—Pain—Gemcitabine—kidney cancer	2.33e-05	0.000188	CcSEcCtD
Ponatinib—Constipation—Gemcitabine—kidney cancer	2.33e-05	0.000188	CcSEcCtD
Ponatinib—Nausea—Erlotinib—kidney cancer	2.33e-05	0.000188	CcSEcCtD
Ponatinib—Alopecia—Capecitabine—kidney cancer	2.33e-05	0.000188	CcSEcCtD
Ponatinib—Dry mouth—Paclitaxel—kidney cancer	2.33e-05	0.000188	CcSEcCtD
Ponatinib—Diarrhoea—Sunitinib—kidney cancer	2.32e-05	0.000188	CcSEcCtD
Ponatinib—Mental disorder—Capecitabine—kidney cancer	2.31e-05	0.000187	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—kidney cancer	2.31e-05	0.000187	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—kidney cancer	2.3e-05	0.000186	CcSEcCtD
Ponatinib—Erythema—Capecitabine—kidney cancer	2.29e-05	0.000186	CcSEcCtD
Ponatinib—Malnutrition—Capecitabine—kidney cancer	2.29e-05	0.000186	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—kidney cancer	2.28e-05	0.000185	CcSEcCtD
Ponatinib—Oedema—Paclitaxel—kidney cancer	2.28e-05	0.000184	CcSEcCtD
Ponatinib—Abdominal pain—Vincristine—kidney cancer	2.27e-05	0.000184	CcSEcCtD
Ponatinib—Body temperature increased—Vincristine—kidney cancer	2.27e-05	0.000184	CcSEcCtD
Ponatinib—Infection—Paclitaxel—kidney cancer	2.27e-05	0.000183	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—kidney cancer	2.25e-05	0.000182	CcSEcCtD
Ponatinib—Dizziness—Sunitinib—kidney cancer	2.25e-05	0.000182	CcSEcCtD
Ponatinib—Vomiting—Sorafenib—kidney cancer	2.24e-05	0.000181	CcSEcCtD
Ponatinib—Nervous system disorder—Paclitaxel—kidney cancer	2.24e-05	0.000181	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—kidney cancer	2.23e-05	0.000181	CcSEcCtD
Ponatinib—Thrombocytopenia—Paclitaxel—kidney cancer	2.23e-05	0.000181	CcSEcCtD
Ponatinib—Rash—Sorafenib—kidney cancer	2.22e-05	0.00018	CcSEcCtD
Ponatinib—Dermatitis—Sorafenib—kidney cancer	2.22e-05	0.00018	CcSEcCtD
Ponatinib—Back pain—Capecitabine—kidney cancer	2.22e-05	0.000179	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—kidney cancer	2.22e-05	0.000179	CcSEcCtD
Ponatinib—Skin disorder—Paclitaxel—kidney cancer	2.22e-05	0.000179	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	2.21e-05	0.000179	CcSEcCtD
Ponatinib—Headache—Sorafenib—kidney cancer	2.21e-05	0.000179	CcSEcCtD
Ponatinib—Muscle spasms—Capecitabine—kidney cancer	2.21e-05	0.000178	CcSEcCtD
Ponatinib—Hyperhidrosis—Paclitaxel—kidney cancer	2.2e-05	0.000178	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—kidney cancer	2.2e-05	0.000178	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—kidney cancer	2.2e-05	0.000178	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.17e-05	0.000175	CcSEcCtD
Ponatinib—Vision blurred—Capecitabine—kidney cancer	2.16e-05	0.000175	CcSEcCtD
Ponatinib—Vomiting—Sunitinib—kidney cancer	2.16e-05	0.000175	CcSEcCtD
Ponatinib—Body temperature increased—Gemcitabine—kidney cancer	2.15e-05	0.000174	CcSEcCtD
Ponatinib—Rash—Sunitinib—kidney cancer	2.14e-05	0.000173	CcSEcCtD
Ponatinib—Dermatitis—Sunitinib—kidney cancer	2.14e-05	0.000173	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—kidney cancer	2.14e-05	0.000173	CcSEcCtD
Ponatinib—Headache—Sunitinib—kidney cancer	2.13e-05	0.000172	CcSEcCtD
Ponatinib—Anaemia—Capecitabine—kidney cancer	2.12e-05	0.000171	CcSEcCtD
Ponatinib—Nausea—Sorafenib—kidney cancer	2.1e-05	0.00017	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—kidney cancer	2.08e-05	0.000168	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	2.08e-05	0.000168	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—kidney cancer	2.07e-05	0.000167	CcSEcCtD
Ponatinib—Insomnia—Paclitaxel—kidney cancer	2.06e-05	0.000167	CcSEcCtD
Ponatinib—Asthenia—Vincristine—kidney cancer	2.06e-05	0.000167	CcSEcCtD
Ponatinib—Leukopenia—Capecitabine—kidney cancer	2.05e-05	0.000166	CcSEcCtD
Ponatinib—Paraesthesia—Paclitaxel—kidney cancer	2.05e-05	0.000166	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—kidney cancer	2.04e-05	0.000165	CcSEcCtD
Ponatinib—Dyspnoea—Paclitaxel—kidney cancer	2.03e-05	0.000164	CcSEcCtD
Ponatinib—Rash—Dactinomycin—kidney cancer	2.03e-05	0.000164	CcSEcCtD
Ponatinib—Nausea—Sunitinib—kidney cancer	2.02e-05	0.000163	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—kidney cancer	2.01e-05	0.000163	CcSEcCtD
Ponatinib—Dyspepsia—Paclitaxel—kidney cancer	2.01e-05	0.000162	CcSEcCtD
Ponatinib—Cough—Capecitabine—kidney cancer	2e-05	0.000162	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—kidney cancer	1.98e-05	0.00016	CcSEcCtD
Ponatinib—Decreased appetite—Paclitaxel—kidney cancer	1.98e-05	0.00016	CcSEcCtD
Ponatinib—Hypertension—Capecitabine—kidney cancer	1.98e-05	0.00016	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.97e-05	0.00016	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.97e-05	0.000159	CcSEcCtD
Ponatinib—Fatigue—Paclitaxel—kidney cancer	1.97e-05	0.000159	CcSEcCtD
Ponatinib—Diarrhoea—Vincristine—kidney cancer	1.96e-05	0.000159	CcSEcCtD
Ponatinib—Asthenia—Gemcitabine—kidney cancer	1.95e-05	0.000158	CcSEcCtD
Ponatinib—Myalgia—Capecitabine—kidney cancer	1.95e-05	0.000158	CcSEcCtD
Ponatinib—Arthralgia—Capecitabine—kidney cancer	1.95e-05	0.000158	CcSEcCtD
Ponatinib—Pain—Paclitaxel—kidney cancer	1.95e-05	0.000158	CcSEcCtD
Ponatinib—Constipation—Paclitaxel—kidney cancer	1.95e-05	0.000158	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.94e-05	0.000157	CcSEcCtD
Ponatinib—Pruritus—Gemcitabine—kidney cancer	1.93e-05	0.000156	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—kidney cancer	1.92e-05	0.000155	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—kidney cancer	1.91e-05	0.000155	CcSEcCtD
Ponatinib—Dry mouth—Capecitabine—kidney cancer	1.91e-05	0.000154	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—kidney cancer	1.91e-05	0.000154	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—kidney cancer	1.9e-05	0.000154	CcSEcCtD
Ponatinib—Dizziness—Vincristine—kidney cancer	1.9e-05	0.000154	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—kidney cancer	1.89e-05	0.000153	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—kidney cancer	1.89e-05	0.000153	CcSEcCtD
Ponatinib—Oedema—Capecitabine—kidney cancer	1.87e-05	0.000151	CcSEcCtD
Ponatinib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.87e-05	0.000151	CcSEcCtD
Ponatinib—Diarrhoea—Gemcitabine—kidney cancer	1.86e-05	0.000151	CcSEcCtD
Ponatinib—Infection—Capecitabine—kidney cancer	1.86e-05	0.00015	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—kidney cancer	1.85e-05	0.00015	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—kidney cancer	1.84e-05	0.000149	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—kidney cancer	1.84e-05	0.000149	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—kidney cancer	1.84e-05	0.000149	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—kidney cancer	1.84e-05	0.000148	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—kidney cancer	1.83e-05	0.000148	CcSEcCtD
Ponatinib—Vomiting—Vincristine—kidney cancer	1.83e-05	0.000148	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—kidney cancer	1.82e-05	0.000147	CcSEcCtD
Ponatinib—Rash—Vincristine—kidney cancer	1.81e-05	0.000146	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—kidney cancer	1.81e-05	0.000146	CcSEcCtD
Ponatinib—Dermatitis—Vincristine—kidney cancer	1.81e-05	0.000146	CcSEcCtD
Ponatinib—Abdominal pain—Paclitaxel—kidney cancer	1.8e-05	0.000146	CcSEcCtD
Ponatinib—Body temperature increased—Paclitaxel—kidney cancer	1.8e-05	0.000146	CcSEcCtD
Ponatinib—Headache—Vincristine—kidney cancer	1.8e-05	0.000146	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.79e-05	0.000145	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—kidney cancer	1.78e-05	0.000144	CcSEcCtD
Ponatinib—Vomiting—Gemcitabine—kidney cancer	1.73e-05	0.00014	CcSEcCtD
Ponatinib—Rash—Gemcitabine—kidney cancer	1.72e-05	0.000139	CcSEcCtD
Ponatinib—Dermatitis—Gemcitabine—kidney cancer	1.72e-05	0.000139	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—kidney cancer	1.71e-05	0.000138	CcSEcCtD
Ponatinib—Headache—Gemcitabine—kidney cancer	1.71e-05	0.000138	CcSEcCtD
Ponatinib—Nausea—Vincristine—kidney cancer	1.71e-05	0.000138	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.71e-05	0.000138	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—kidney cancer	1.7e-05	0.000137	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—kidney cancer	1.69e-05	0.000137	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—kidney cancer	1.69e-05	0.000137	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—kidney cancer	1.68e-05	0.000136	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—kidney cancer	1.67e-05	0.000135	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—kidney cancer	1.67e-05	0.000135	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—kidney cancer	1.67e-05	0.000135	CcSEcCtD
Ponatinib—Dyspepsia—Capecitabine—kidney cancer	1.65e-05	0.000133	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—kidney cancer	1.64e-05	0.000132	CcSEcCtD
Ponatinib—Asthenia—Paclitaxel—kidney cancer	1.64e-05	0.000132	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—kidney cancer	1.63e-05	0.000132	CcSEcCtD
Ponatinib—Nausea—Gemcitabine—kidney cancer	1.62e-05	0.000131	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.62e-05	0.000131	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—kidney cancer	1.61e-05	0.000131	CcSEcCtD
Ponatinib—Pruritus—Paclitaxel—kidney cancer	1.61e-05	0.000131	CcSEcCtD
Ponatinib—Pain—Capecitabine—kidney cancer	1.6e-05	0.000129	CcSEcCtD
Ponatinib—Constipation—Capecitabine—kidney cancer	1.6e-05	0.000129	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—kidney cancer	1.59e-05	0.000128	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—kidney cancer	1.58e-05	0.000127	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—kidney cancer	1.58e-05	0.000127	CcSEcCtD
Ponatinib—Diarrhoea—Paclitaxel—kidney cancer	1.56e-05	0.000126	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—kidney cancer	1.54e-05	0.000125	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—kidney cancer	1.53e-05	0.000124	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—kidney cancer	1.53e-05	0.000124	CcSEcCtD
Ponatinib—Chills—Doxorubicin—kidney cancer	1.52e-05	0.000123	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—kidney cancer	1.52e-05	0.000123	CcSEcCtD
Ponatinib—Dizziness—Paclitaxel—kidney cancer	1.51e-05	0.000122	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—kidney cancer	1.5e-05	0.000121	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—kidney cancer	1.49e-05	0.00012	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—kidney cancer	1.48e-05	0.00012	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—kidney cancer	1.48e-05	0.00012	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—kidney cancer	1.48e-05	0.00012	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—kidney cancer	1.48e-05	0.00012	CcSEcCtD
Ponatinib—Vomiting—Paclitaxel—kidney cancer	1.45e-05	0.000117	CcSEcCtD
Ponatinib—Rash—Paclitaxel—kidney cancer	1.44e-05	0.000116	CcSEcCtD
Ponatinib—Dermatitis—Paclitaxel—kidney cancer	1.44e-05	0.000116	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—kidney cancer	1.43e-05	0.000116	CcSEcCtD
Ponatinib—Headache—Paclitaxel—kidney cancer	1.43e-05	0.000116	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—kidney cancer	1.42e-05	0.000115	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—kidney cancer	1.39e-05	0.000113	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—kidney cancer	1.37e-05	0.000111	CcSEcCtD
Ponatinib—Nausea—Paclitaxel—kidney cancer	1.35e-05	0.00011	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—kidney cancer	1.34e-05	0.000109	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—kidney cancer	1.32e-05	0.000107	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—kidney cancer	1.32e-05	0.000107	CcSEcCtD
Ponatinib—Cough—Doxorubicin—kidney cancer	1.29e-05	0.000104	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—kidney cancer	1.28e-05	0.000104	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—kidney cancer	1.28e-05	0.000103	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—kidney cancer	1.26e-05	0.000102	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—kidney cancer	1.26e-05	0.000102	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.25e-05	0.000101	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—kidney cancer	1.24e-05	0.0001	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—kidney cancer	1.23e-05	9.96e-05	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—kidney cancer	1.21e-05	9.76e-05	CcSEcCtD
Ponatinib—Infection—Doxorubicin—kidney cancer	1.2e-05	9.7e-05	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—kidney cancer	1.19e-05	9.63e-05	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—kidney cancer	1.18e-05	9.57e-05	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—kidney cancer	1.18e-05	9.56e-05	CcSEcCtD
Ponatinib—Rash—Capecitabine—kidney cancer	1.18e-05	9.55e-05	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—kidney cancer	1.18e-05	9.54e-05	CcSEcCtD
Ponatinib—Headache—Capecitabine—kidney cancer	1.17e-05	9.48e-05	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—kidney cancer	1.17e-05	9.48e-05	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—kidney cancer	1.17e-05	9.43e-05	CcSEcCtD
Ponatinib—Nausea—Capecitabine—kidney cancer	1.11e-05	8.99e-05	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.1e-05	8.89e-05	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—kidney cancer	1.09e-05	8.83e-05	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—kidney cancer	1.08e-05	8.76e-05	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—kidney cancer	1.08e-05	8.7e-05	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—kidney cancer	1.06e-05	8.59e-05	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—kidney cancer	1.05e-05	8.48e-05	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.04e-05	8.43e-05	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—kidney cancer	1.04e-05	8.41e-05	CcSEcCtD
Ponatinib—Pain—Doxorubicin—kidney cancer	1.03e-05	8.35e-05	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—kidney cancer	1.03e-05	8.35e-05	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—kidney cancer	9.87e-06	7.98e-05	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—kidney cancer	9.54e-06	7.71e-05	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—kidney cancer	9.54e-06	7.71e-05	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—kidney cancer	8.66e-06	7e-05	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—kidney cancer	8.54e-06	6.9e-05	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—kidney cancer	8.26e-06	6.68e-05	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—kidney cancer	7.98e-06	6.45e-05	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—kidney cancer	7.67e-06	6.21e-05	CcSEcCtD
Ponatinib—Rash—Doxorubicin—kidney cancer	7.61e-06	6.15e-05	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—kidney cancer	7.6e-06	6.15e-05	CcSEcCtD
Ponatinib—Headache—Doxorubicin—kidney cancer	7.56e-06	6.11e-05	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—kidney cancer	7.17e-06	5.8e-05	CcSEcCtD
Ponatinib—LCK—Signaling Pathways—KDR—kidney cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—kidney cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RELA—kidney cancer	1.15e-06	1.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RELA—kidney cancer	1.15e-06	1.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—kidney cancer	1.14e-06	1.3e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—kidney cancer	1.14e-06	1.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—PIK3CA—kidney cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—RAF1—kidney cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—kidney cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—RELA—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1B—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK3—kidney cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK3—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MAPK1—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MAPK1—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK3—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MTOR—kidney cancer	1.13e-06	1.28e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—kidney cancer	1.12e-06	1.28e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MTOR—kidney cancer	1.12e-06	1.28e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP1A1—kidney cancer	1.12e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—JUN—kidney cancer	1.12e-06	1.28e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—PIK3CA—kidney cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—PIK3CA—kidney cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTP1—kidney cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1B—kidney cancer	1.11e-06	1.27e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CTNNB1—kidney cancer	1.11e-06	1.27e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MTOR—kidney cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—kidney cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—kidney cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—kidney cancer	1.1e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—kidney cancer	1.09e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1B—kidney cancer	1.09e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTEN—kidney cancer	1.09e-06	1.23e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—kidney cancer	1.08e-06	1.23e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—JUN—kidney cancer	1.08e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK1—kidney cancer	1.08e-06	1.22e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK1—kidney cancer	1.08e-06	1.22e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK1—kidney cancer	1.07e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CTNNB1—kidney cancer	1.07e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PIK3CA—kidney cancer	1.07e-06	1.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—kidney cancer	1.07e-06	1.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HIF1A—kidney cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—kidney cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—kidney cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TSC2—kidney cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—kidney cancer	1.06e-06	1.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—JUN—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APC—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1B—kidney cancer	1.06e-06	1.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1B—kidney cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CTNNB1—kidney cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—kidney cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—RAF1—kidney cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—kidney cancer	1.04e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1B—kidney cancer	1.04e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—kidney cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—kidney cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—kidney cancer	1.03e-06	1.18e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CTNNB1—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MTOR—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—kidney cancer	1.03e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CRABP1—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KDR—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—kidney cancer	1.02e-06	1.16e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—kidney cancer	1.02e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RAF1—kidney cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—kidney cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RELA—kidney cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—kidney cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—kidney cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—JUN—kidney cancer	1.01e-06	1.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	1.01e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—kidney cancer	1e-06	1.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—JUN—kidney cancer	1e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—kidney cancer	1e-06	1.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—kidney cancer	9.98e-07	1.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—kidney cancer	9.96e-07	1.13e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	9.96e-07	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—JUN—kidney cancer	9.93e-07	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MTOR—kidney cancer	9.91e-07	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—kidney cancer	9.86e-07	1.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—kidney cancer	9.8e-07	1.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—kidney cancer	9.78e-07	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—kidney cancer	9.73e-07	1.11e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—kidney cancer	9.73e-07	1.11e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1A1—kidney cancer	9.73e-07	1.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	9.71e-07	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1B—kidney cancer	9.63e-07	1.09e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—kidney cancer	9.61e-07	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ITPR2—kidney cancer	9.48e-07	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—kidney cancer	9.43e-07	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—kidney cancer	9.38e-07	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—kidney cancer	9.38e-07	1.07e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—kidney cancer	9.34e-07	1.06e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—kidney cancer	9.33e-07	1.06e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—kidney cancer	9.32e-07	1.06e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—kidney cancer	9.3e-07	1.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—kidney cancer	9.3e-07	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK3—kidney cancer	9.27e-07	1.05e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—kidney cancer	9.26e-07	1.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—kidney cancer	9.17e-07	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—kidney cancer	9.1e-07	1.03e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—kidney cancer	9.1e-07	1.03e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—kidney cancer	9.02e-07	1.03e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—kidney cancer	8.94e-07	1.02e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—kidney cancer	8.93e-07	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—kidney cancer	8.92e-07	1.01e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—kidney cancer	8.87e-07	1.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—kidney cancer	8.87e-07	1.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—kidney cancer	8.85e-07	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—kidney cancer	8.82e-07	1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—kidney cancer	8.82e-07	1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—kidney cancer	8.79e-07	9.99e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—kidney cancer	8.78e-07	9.98e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	8.77e-07	9.96e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—kidney cancer	8.76e-07	9.96e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—kidney cancer	8.68e-07	9.86e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—kidney cancer	8.68e-07	9.86e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—kidney cancer	8.68e-07	9.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—kidney cancer	8.65e-07	9.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ACHE—kidney cancer	8.65e-07	9.83e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—kidney cancer	8.56e-07	9.73e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—kidney cancer	8.56e-07	9.73e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—kidney cancer	8.52e-07	9.68e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—kidney cancer	8.49e-07	9.65e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—kidney cancer	8.48e-07	9.63e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—kidney cancer	8.42e-07	9.57e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—kidney cancer	8.37e-07	9.52e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—kidney cancer	8.34e-07	9.47e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—kidney cancer	8.33e-07	9.47e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—kidney cancer	8.33e-07	9.46e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—kidney cancer	8.32e-07	9.45e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—kidney cancer	8.31e-07	9.45e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	8.29e-07	9.43e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RELA—kidney cancer	8.28e-07	9.41e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—kidney cancer	8.23e-07	9.35e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—kidney cancer	8.21e-07	9.33e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SCARB1—kidney cancer	8.19e-07	9.3e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—kidney cancer	8.15e-07	9.26e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—kidney cancer	8.13e-07	9.24e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—kidney cancer	8.12e-07	9.23e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS1—kidney cancer	8.1e-07	9.21e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—kidney cancer	8.09e-07	9.19e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—kidney cancer	8.07e-07	9.17e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—kidney cancer	8.02e-07	9.11e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.99e-07	9.08e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—kidney cancer	7.99e-07	9.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMD7—kidney cancer	7.95e-07	9.03e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—kidney cancer	7.91e-07	8.99e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	7.89e-07	8.97e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—kidney cancer	7.87e-07	8.95e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—kidney cancer	7.81e-07	8.88e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—kidney cancer	7.73e-07	8.79e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—kidney cancer	7.69e-07	8.75e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—kidney cancer	7.66e-07	8.7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	7.62e-07	8.66e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—kidney cancer	7.58e-07	8.61e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—kidney cancer	7.53e-07	8.56e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—kidney cancer	7.47e-07	8.49e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—kidney cancer	7.46e-07	8.48e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	7.45e-07	8.47e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	7.44e-07	8.46e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—kidney cancer	7.38e-07	8.39e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—kidney cancer	7.37e-07	8.38e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—kidney cancer	7.37e-07	8.37e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—kidney cancer	7.36e-07	8.37e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RELA—kidney cancer	7.33e-07	8.33e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—kidney cancer	7.31e-07	8.31e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—kidney cancer	7.28e-07	8.28e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—kidney cancer	7.27e-07	8.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—kidney cancer	7.25e-07	8.25e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—kidney cancer	7.25e-07	8.24e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—kidney cancer	7.23e-07	8.22e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—kidney cancer	7.21e-07	8.2e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	7.2e-07	8.18e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—kidney cancer	7.19e-07	8.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	7.19e-07	8.17e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—kidney cancer	7.13e-07	8.1e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—kidney cancer	7.11e-07	8.09e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—kidney cancer	7.07e-07	8.03e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—kidney cancer	7.02e-07	7.98e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—kidney cancer	7e-07	7.95e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—kidney cancer	6.96e-07	7.91e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—kidney cancer	6.86e-07	7.8e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	6.85e-07	7.78e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—kidney cancer	6.81e-07	7.74e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—kidney cancer	6.78e-07	7.7e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—kidney cancer	6.75e-07	7.67e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—kidney cancer	6.68e-07	7.59e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—kidney cancer	6.64e-07	7.55e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—kidney cancer	6.62e-07	7.53e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—kidney cancer	6.6e-07	7.5e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—kidney cancer	6.57e-07	7.47e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—kidney cancer	6.44e-07	7.31e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—kidney cancer	6.42e-07	7.3e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—kidney cancer	6.37e-07	7.24e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—kidney cancer	6.34e-07	7.2e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—kidney cancer	6.32e-07	7.18e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—kidney cancer	6.26e-07	7.11e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—kidney cancer	6.21e-07	7.06e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—kidney cancer	6.04e-07	6.86e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—kidney cancer	6e-07	6.81e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—kidney cancer	5.99e-07	6.81e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—kidney cancer	5.95e-07	6.77e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—kidney cancer	5.84e-07	6.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—kidney cancer	5.83e-07	6.63e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—kidney cancer	5.82e-07	6.62e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—kidney cancer	5.79e-07	6.58e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—kidney cancer	5.74e-07	6.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—kidney cancer	5.7e-07	6.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—kidney cancer	5.67e-07	6.45e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—kidney cancer	5.61e-07	6.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—kidney cancer	5.51e-07	6.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—kidney cancer	5.39e-07	6.12e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—kidney cancer	5.31e-07	6.03e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.22e-07	5.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—kidney cancer	5.16e-07	5.87e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—kidney cancer	5.05e-07	5.74e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—kidney cancer	5.05e-07	5.73e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—kidney cancer	5.04e-07	5.73e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	4.95e-07	5.63e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—kidney cancer	4.79e-07	5.44e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—kidney cancer	4.77e-07	5.42e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—kidney cancer	4.75e-07	5.4e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—kidney cancer	4.4e-07	5e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—kidney cancer	4.38e-07	4.98e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—kidney cancer	4.24e-07	4.82e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—kidney cancer	4.14e-07	4.71e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—kidney cancer	4.11e-07	4.67e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—kidney cancer	3.89e-07	4.42e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—kidney cancer	3.56e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—kidney cancer	3.11e-07	3.53e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—kidney cancer	3.1e-07	3.52e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.92e-07	3.32e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—kidney cancer	2.71e-07	3.08e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.91e-07	2.17e-06	CbGpPWpGaD
